In an unprecedented wave of manufacturing reconfiguration, the pharmaceutical industry is witnessing a seismic shift in how blockbuster drug production is structured. Between mid-March and mid-April 2026 alone, three major facility sales from pharmaceutical companies to contract development and manufacturing organizations (CDMOs) were completed — a pace that dramatically outstrips the two such deals recorded in the preceding eight months.
This accelerated transfer of physical manufacturing assets from household pharma names to specialized outsourcing partners signals more than routine portfolio reshuffling. It reflects a fundamental strategic pivot driven by tariff uncertainties, US onshoring mandates, and the growing recognition that flexible, outsourced manufacturing may be the most resilient path forward.
Samsung Biologics acquires GSK's Rockville facility. The crown jewel of the recent deal flurry, Samsung's acquisition of GSK's biologics manufacturing site in Rockville, Maryland, marks the South Korean CDMO's first US manufacturing presence. The facility adds 60,000 liters of drug substance capacity to Samsung's global portfolio, boosting its total to 845,000 liters — an almost 8% increase. Critically, GSK will continue to source products from the site under a supply agreement, while Samsung plans further investments to expand capabilities and pursue additional contract manufacturing clients. This hybrid arrangement — where the seller becomes a customer — is emerging as a template for future transactions.
Rois acquires BMS injectables facility in Phoenix. Laboratorios Farmaceuticos Rovi's CDMO arm, Rois, completed its purchase of a Bristol Myers Squibb injectables manufacturing site in Phoenix, Arizona. Like the GSK-Samsung deal, the agreement includes provisions for continued manufacturing of BMS products at the newly acquired site, ensuring supply continuity while granting the CDMO a strategic US manufacturing footprint.
Adragos Pharma acquires Sanofi's French sterile fill-finish facility. The only non-US deal in the recent cluster saw Adragos Pharma finalize its acquisition of Sanofi's sterile fill-finish site in Maisons-Alfort, France. The move strengthens Adragos's European injectables network and underscores that the manufacturing reconfiguration trend is global, not confined to American soil.
These transactions did not occur in a vacuum. They are the direct result of pharmaceutical companies retooling their manufacturing strategies in response to escalating tariff threats and political pressure to onshore domestic production. In 2025, some of the industry's largest players announced transformative US manufacturing investments: Roche, Novartis, Eli Lilly, and Johnson & Johnson collectively pledged $155 billion in domestic manufacturing capacity.
However, building greenfield facilities takes years and carries enormous capital risk. Acquiring and then divesting existing sites — or selling them to specialized CDMOs that can serve multiple clients — offers a faster, more capital-efficient alternative. For pharmaceutical companies, the calculus is clear: maintain supply chain security without bearing the full cost and operational burden of owned manufacturing infrastructure.
The result is a growing pipeline of pharma-to-CDMO facility transfers. Before the recent three-deal burst, Celltrion had already completed its acquisition of Eli Lilly's Branchburg, New Jersey site in January 2026, and Thermo Fisher Scientific purchased a Sanofi sterile fill-finish and packaging facility in Ridgefield, Connecticut back in September 2025. The pattern is unmistakable.
For CDMOs, these facility acquisitions represent a rare convergence of strategic opportunity and market timing. The global CDMO market, valued at over $200 billion, is projected to grow at a compound annual rate of 7-9% through 2030, and the current wave of pharma manufacturing divestitures is providing a significant accelerant.
For API and intermediate suppliers, the implications are equally profound. As CDMOs expand their manufacturing footprints and take on additional clients, demand for active pharmaceutical ingredients, advanced intermediates, and starting materials will increase. CDMOs managing multiple product lines require diversified supply chains — creating opportunities for suppliers who can offer reliable, scalable, and cost-effective API solutions across therapeutic categories.
The trend also highlights the growing importance of CDMO-API partnerships. As outsourcing companies take on more complex manufacturing — from biologics to sterile injectables — the quality and consistency of API supply becomes a critical differentiator. Suppliers who can demonstrate robust quality systems, regulatory compliance, and flexible production capacity will be best positioned to capture this growing demand.
The current wave of pharma-to-CDMO facility transfers is likely just the beginning. As tariff uncertainties persist, as biologics and complex generics grow in importance, and as pharmaceutical companies seek to optimize their capital allocation, the CDMO sector will continue to absorb manufacturing capacity at an accelerating pace.
For industry stakeholders — from CDMOs and API suppliers to pharmaceutical companies and investors — the message is clear: the future of drug manufacturing is increasingly outsourced, and the organizations that adapt to this new paradigm will capture disproportionate value in the years ahead.
The current wave of pharma-to-CDMO facility transfers is likely just the beginning. As tariff uncertainties persist, as biologics and complex generics grow in importance, and as pharmaceutical companies seek to optimize capital allocation, the CDMO sector will continue to absorb manufacturing capacity at an accelerating pace.
For industry stakeholders — from CDMOs and API suppliers to pharmaceutical companies and investors — the future of drug manufacturing is increasingly outsourced, and the organizations that adapt to this new paradigm will capture disproportionate value in the years ahead.
